[DOI] [PMC free article] [PubMed] [Google Scholar] 73.Xie Y, McGill MR, Dorko K, Kumer SC, Schmitt TM, Forster J, Jaeschke H
Trump Administration Pushed for Cheaper Weight-Loss Drug Prices The Trump administration announced plans in November 2025 to reduce the cost of GLP-1 medications for Americans after reaching a deal with drug manufacturers Eli Lilly and Novo Nordisk
Leaders in Connecticut, facing a $290 million Medicaid deficit, have moved away from an initial proposal to cover GLP-1s for obesity, and are now requiring patients to get a Type 2 diabetes diagnosis to qualify for coverage
PMID: 213 WangFQianFZhangQZhaoJCenJZhangJet al
Many people report that theyve adapted to these conditions to the point of not fully recognizing them as symptoms until they begin to change
GLP-1 drugs may reduce pressure inside the skull by lowering the production of cerebrospinal fluid, which bathes the brain and spinal cord, the researchers suggested